Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics.
In addition to its essential role in immune defense, the complement system contributes to tissue damage in many clinical conditions. Thus, there is a pressing need to develop therapeutically effective complement inhibitors to prevent these adverse effects. This concept, though old, received little scientific attention until recently. Data from animal models of diseases that have been produced using complement-deficient, knockout, and transgenic animals, as well as data demonstrating that complement proteins are produced in many important tissue sites (including the brain) have attracted the interest of many basic research scientists and applied scientists from the biotechnology field and larger pharmaceutical firms. This resurgence of interest has generated a wealth of new information in the field of complement inhibition. In this article, we comprehensively review up-to-date information in the field of complement inhibitors.
Sahu
A
A
Protein Chemistry Laboratory, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia 19104, USA.
Lambris
J D
JD
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003167:Complement Activation; D003169:Complement Inactivator Proteins / Q000009:adverse effects / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology; D011994:Recombinant Proteins / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D003169:Complement Inactivator Proteins; D011994:Recombinant Proteins